ライフサイエンスコーパス: low-density lipoprotein cholesterol

1 29) for triglycerides, and 95.0% (19/20) for low-density lipoprotein cholesterol.

2 ardiovascular risk as on-treatment levels of low-density lipoprotein cholesterol.

3 on trial in 45- to 64-year-old men with high low-density lipoprotein cholesterol.

4 ciated with lower adult weight and total and low-density lipoprotein cholesterol.

5 to quantify the effect of statin on lowering low-density lipoprotein cholesterol.

6 intestinal cholesterol absorption and lowers low-density lipoprotein cholesterol.

7 of action may achieve further reductions in low-density lipoprotein cholesterol.

8 he development of novel treatment for plasma low-density lipoprotein cholesterol.

9 blood pressure but a markedly lower level of low-density lipoprotein cholesterol.

10 all 3 goals for aspirin, blood pressure, and low-density lipoprotein cholesterol.

11 that includes potent statin therapy and low low-density lipoprotein cholesterol.

12 n, blood pressure, albuminuria, smoking, and low-density lipoprotein cholesterol.

13 ulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol.

14 ent-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

15 lycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

16 ciate genetically with levels of remnant and low-density lipoprotein-cholesterol.

17 xcept for an inverse association of FT4 with low-density lipoprotein-cholesterol.

18 l/L; 95% CI: 0.10, 0.24 mmol/L; P < 0.0001), low-density lipoprotein cholesterol (0.12 mmol/L; 95% CI

19 tervention group had greater improvements in low-density lipoprotein cholesterol (-0.2 mmol/l; p < 0.

20 ipoprotein cholesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and

21 ]), obesity (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), hig

22 rol, 184.74 mg/dL (178.17-191.31 mg/dL); for low-density lipoprotein cholesterol, 109.23 mg/dL (103.6

23 cholesterol (-8.4% and -9.2%, respectively), low-density lipoprotein cholesterol (-11.3% and -13.6%),

24 idence interval, 18-27; P<1.0x10(-4)), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% co

25 y lipoprotein cholesterol, 10 of 35 loci for low-density lipoprotein cholesterol, 13 of 44 loci for t

26 benefit based versus risk based) with higher low-density lipoprotein cholesterol (140 versus133 mg/dL

27 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non

28 gh-density lipoprotein cholesterol (2 SNPs), low-density lipoprotein cholesterol (4 SNPs), and trigly

29 patients after acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were

30 ed on 58 single-nucleotide polymorphisms for low-density lipoprotein cholesterol, 71 single-nucleotid

31 iation evidence were found on chromosomes 7 (low-density lipoprotein cholesterol), 8 (high-density li

32 -8 mg/dl for total cholesterol, -8 mg/dl for low-density lipoprotein cholesterol, +8 mg/dl for remnan

33 nt of saturated with unsaturated fats lowers low-density lipoprotein cholesterol, a cause of atherosc

34 e subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patie

35 ype natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipopr

36 d Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gen

37 The concentrations of low-density lipoprotein cholesterol and C-reactive prote

38 n/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular e

39 atory site for blood lipids, such as for the low-density lipoprotein cholesterol and coronary artery

40 me-wide significant variants associated with low-density lipoprotein cholesterol and coronary heart d

41 heart disease independent of the effects of low-density lipoprotein cholesterol and high-density lip

42 The interaction between low-density lipoprotein cholesterol and IHD genetic load

43 trials, showing it is a potent inhibitor of low-density lipoprotein cholesterol and is mediated thro

44 creased body mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) l

45 nsistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of li

46 Prevention Study) randomized men with raised low-density lipoprotein cholesterol and no history of my

47 1.01-1.59; P=0.04), which was independent of low-density lipoprotein cholesterol and other factors.

48 lable Dutch Lipid Clinic criteria, including low-density lipoprotein cholesterol and personal and fam

49 s a promising new target for lowering plasma low-density lipoprotein cholesterol and preventing cardi

50 nd robustly associated with fasting very-low low-density lipoprotein cholesterol and TG.

51 gh elevated levels of nonfasting remnant and low-density lipoprotein cholesterol and through elevated

52 tion of variance explained, particularly for low-density lipoprotein cholesterol and total cholestero

53 f treatment initiation, associations between low-density lipoprotein cholesterol and treatment initia

54 Low-density lipoprotein cholesterol and triglyceride lev

55 significant associations only with levels of low-density lipoprotein cholesterol and triglycerides (a

56 Elevated low-density lipoprotein cholesterol and triglycerides ar

57 The confluence of low-density lipoprotein cholesterol and triglycerides ge

58 as lomitapide, can effectively lower plasma low-density lipoprotein-cholesterol and apolipoprotein B

59 (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical varia

60 with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure.

61 concentrations of triglycerides (TGs), very-low-density lipoprotein cholesterol, and glucose were si

62 ntrol subjects and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower

63 betes mellitus, high-density lipoprotein and low-density lipoprotein cholesterol, and IHD to create G

64 High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride le

65 d with high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides f

66 terol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides.

67 serum levels of total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides.

68 s and cumulative exposure to lower levels of low-density lipoprotein cholesterol are not associated w

69 oach using only childhood lipid measures for low-density lipoprotein cholesterol (area under the rece

70 atment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reac

71 pe 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently

72 Unregulated uptake of low-density lipoprotein cholesterol by circulating monoc

73 sult in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide informat

74 Pravastatin lowered low-density lipoprotein cholesterol (change in SD units

75 ificantly lower median time-weighted average low-density lipoprotein cholesterol compared with placeb

76 In secondary analyses conditioning on low-density lipoprotein cholesterol concentration, the e

77 and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol concentrations withi

78 t-day humans, including variants involved in low-density lipoprotein cholesterol concentrations, schi

79 Soy protein directly lowers blood low-density lipoprotein-cholesterol concentrations, and

80 nic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery dis

81 A and NPHSII, respectively; both p < 0.001), low-density lipoprotein cholesterol (correlation coeffic

82 rides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, creatine kinase, th

83 %, 2.3 (95% CI, 0.6-8.6), and 176.5; and for low-density lipoprotein cholesterol criteria, 0.5%, 5%,

84 t showed differential responses in total and low-density lipoprotein cholesterol (decreased in LFHC g

85 s for neurocognitive impairment per 20 mg/dL low-density lipoprotein cholesterol decrements were 1.02

86 These changes in low-density lipoprotein cholesterol equate to an estimat

87 vascular event, diabetes mellitus, total and low-density lipoprotein cholesterol, estimated glomerula

88 ncing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-de

89 ] and <50 mg/dL [women]), and high levels of low-density lipoprotein cholesterol (fasting laboratory

90 ng insulin, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, di

91 nd is mediated through more rapid removal of low-density lipoprotein cholesterol from the plasma.

92 ipoprotein cholesterol, from 5.0 to 8.8% for low-density lipoprotein cholesterol, from 5.5 to 8.8% fo

93 ides greater than or equal to 62.5 mg/dL and low-density lipoprotein cholesterol greater than or equa

94 was >/=7.5% were considered statin eligible: low-density lipoprotein cholesterol >/=160 mg/dL; family

95 burden related to phenotypic FH, defined by low-density lipoprotein cholesterol >/=190 mg/dL, is lik

96 h a third who had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).

97 Children with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1

98 d with the highest versus lowest quartile of low-density lipoprotein cholesterol (>/= 146 versus </=

99 en at baseline included a very high level of low-density lipoprotein cholesterol (>/=190 mg per decil

100 and cardiometabolic outcomes, estimates for low-density lipoprotein cholesterol, HDL cholesterol, tr

101 diabetes duration, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A1c, alb

102 ated to cardiovascular disease risk factors: low-density lipoprotein cholesterol, high-density lipopr

103 Further adjustment for low-density lipoprotein cholesterol, high-density lipopr

104 ns, diabetes mellitus, diabetic medications, low-density lipoprotein cholesterol, high-density lipopr

105 ulating fasting levels of total cholesterol, low-density lipoprotein-cholesterol, high-density lipopr

106 ertensive medication use increased at higher low-density lipoprotein cholesterol in ARIC but not in R

107 of triglycerides to risk was independent of low-density lipoprotein cholesterol in both studies.

108 hibitors were recently approved for lowering low-density lipoprotein cholesterol in heterozygous fami

109 s in the face of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-

110 between multiple-haplotype IBD clusters and low-density lipoprotein cholesterol in the Northern Finl

111 er of ER-derived cholesterol to the MVB when low-density lipoprotein-cholesterol in endosomes is low.

112 A1c was -0.022 +/- 0.53%; however, total and low-density lipoprotein cholesterol increased significan

113 rom triglycerides are a major energy source, low-density lipoprotein cholesterol is critical for cell

114 cholesterol levels in those patients in whom low density lipoprotein cholesterol (LDL-C) reduction is

115 ipoprotein-cholesterol (HDL-C) elevation and low density lipoprotein-cholesterol (LDL-C) reduction in

116 There was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase

117 Plasma levels of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resis

118 For low-density lipoprotein cholesterol (LDL) of 130-159 mg/

119 sting total cholesterol (TC) >/=200 mg/dL or low-density lipoprotein cholesterol (LDL-c) >/=130 mg/dL

120 Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL

121 senting 4 different PCSK9 GOF mutations with low-density lipoprotein cholesterol (LDL-C) >/=70 mg/dL

122 se <126 mg/dl, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl,

123 iglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627).

124 Aggressively managing low-density lipoprotein cholesterol (LDL-C) after myocar

125 rvational studies, and whether low levels of low-density lipoprotein cholesterol (LDL-C) alter this a

126 haracterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelera

127 ma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipop

128 Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associat

129 e characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremel

130 Serum low-density lipoprotein cholesterol (LDL-C) and high-den

131 Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sen

132 ontinuous relationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major ad

133 ment Panel III (NCEP-ATP III) parameters for low-density lipoprotein cholesterol (LDL-C) and other li

134 treatment for the reduction of raised serum low-density lipoprotein cholesterol (LDL-C) and preventi

135 Statins lower low-density lipoprotein cholesterol (LDL-C) and risk of

136 L-C remains a CVD risk factor when levels of low-density lipoprotein cholesterol (LDL-C) and triglyce

137 Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an indep

138 There was significant interaction with low-density lipoprotein cholesterol (LDL-c) at baseline.

139 le uncertainty exists as to whether lowering low-density lipoprotein cholesterol (LDL-C) by inhibitin

140 f statin drugs (n = 1071, 6-104 weeks) found low-density lipoprotein cholesterol (LDL-C) decreases of

141 oring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation.

142 Plasma low-density lipoprotein cholesterol (LDL-C) has been ass

143 elected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown m

144 9), demonstrated marked reductions in plasma low-density lipoprotein cholesterol (LDL-C) in a phase 2

145 /kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 s

146 Low-density lipoprotein cholesterol (LDL-C) is causally

147 Low-density lipoprotein cholesterol (LDL-C) is the tradi

148 The primary end point was low-density lipoprotein cholesterol (LDL-C) level at 6 m

149 Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) level at the

150 essure less than 140/90 mm Hg; diabetes with low-density lipoprotein cholesterol (LDL-C) level less t

151 tients with elevated 10-year risk (>5%) or a low-density lipoprotein cholesterol (LDL-C) level of 4.9

152 y statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of les

153 cluding 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and h

154 noclonal antibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55

155 itors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despi

156 ding of the harmful consequences of elevated low-density lipoprotein cholesterol (LDL-C) levels in yo

157 ter transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels witho

158 the SORT1 locus are strongly associated with low-density lipoprotein cholesterol (LDL-C) levels, as w

159 The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels.

160 isk score (GRS) in CHD risk estimates lowers low-density lipoprotein cholesterol (LDL-C) levels.

161 cludes all patients with marked elevation of low-density lipoprotein cholesterol (LDL-C) levels.

162 malization of vessel function can occur when low-density lipoprotein cholesterol (LDL-C) lowering occ

163 amination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovas

164 yzed samples from 377 subjects with elevated low-density lipoprotein cholesterol (LDL-C) or low HDL-C

165 adults even in the context of low levels of low-density lipoprotein cholesterol (LDL-C) or non-high-

166 was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts bot

167 Low-density lipoprotein cholesterol (LDL-C) reductions w

168 l benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains unce

169 exin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low

170 We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment go

171 Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a stat

172 Median untreated low-density lipoprotein cholesterol (LDL-C) was 239 mg/d

173 vestigated whether the relative reduction in low-density lipoprotein cholesterol (LDL-c) was a good i

174 Importance: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensi

175 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and cerebra

176 tein cholesterol (TC/HDL-C) ratio, estimated low-density lipoprotein cholesterol (LDL-C), and non-HDL

177 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

178 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

179 erized by elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C), is associat

180 Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequent

181 interindividual variability of reductions in low-density lipoprotein cholesterol (LDL-C), non-high-de

182 lisin/kexin type 9 gene (PCSK9) lower plasma low-density lipoprotein cholesterol (LDL-C), protect aga

183 Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerid

184 id traits, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerid

185 rogenic lipoprotein particles, predominantly low-density lipoprotein cholesterol (LDL-C), which is as

186 Importance: Low-density lipoprotein cholesterol (LDL-C)-lowering all

187 randomized controlled trials of statin-based low-density lipoprotein cholesterol (LDL-C)-lowering the

188 orin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing the

189 could be useful for treating high levels of low-density lipoprotein cholesterol (LDL-C).

190 key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C).

191 imarily expressed in the liver and regulates low-density lipoprotein cholesterol (LDL-C).

192 preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C).

193 (-0.02 mmol/l; 95% CI = -0.03 to -0.01) and low-density lipoprotein cholesterol (LDL-C; -0.04 mmol/l

194 d minimal changes in total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-densit

195 igh-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or trig

196 ations in PCSK9 (causing marked increases in low-density lipoprotein cholesterol [LDL-C] concentratio

197 ring of remnant cholesterol (80% relative to low-density lipoprotein cholesterol [LDL-C]), but only m

198 on between lipid markers (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-densit

199 igh-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total chole

200 Low-density lipoprotein cholesterol(LDL-C) is a well est

201 the CC-genotype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cho

202 with triglycerides less than 62.5 mg/dL and low-density lipoprotein cholesterol less than 110 mg/dL

203 After adjustment for risk factors, low-density lipoprotein cholesterol less than 62.5 mg/dL

204 (women), triglyceride level <100 mg/dL, and low-density lipoprotein cholesterol level <100 mg/dL (n

205 ) (targets: glycated hemoglobin level <7.0%, low-density lipoprotein cholesterol level <100 mg/dL, sy

206 y (targets: glycated hemoglobin level <6.0%, low-density lipoprotein cholesterol level <70 mg/dL, hig

207 CI, -0.82 to -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [

208 gical cohorts, we stratified participants by low-density lipoprotein cholesterol level at index ages

209 rriers; 46% of statin-treated carriers had a low-density lipoprotein cholesterol level below 100 mg/d

210 ut clinical atherosclerotic CVD or diabetes, low-density lipoprotein cholesterol level between 70 and

211 , but approval rates did not vary by patient low-density lipoprotein cholesterol level nor statin use

212 ants on stable antiretroviral therapy with a low-density lipoprotein cholesterol level of </=130 mg/d

213 The overall mean low-density lipoprotein cholesterol level was 26.5% lowe

214 The decrease of low-density lipoprotein cholesterol level was significan

215 hrologist or if proteinuria, blood pressure, low-density lipoprotein cholesterol level, and glycemia

216 Age, low-density lipoprotein cholesterol level, and pre-ART H

217 crease to 2.02-mg/dL increase]) (n = 9); and low-density-lipoprotein cholesterol level decreased by 0

218 For the primary analysis, low-density lipoprotein cholesterol levels >/=190 and <1

219 d those with known ASCVD, diabetes mellitus, low-density lipoprotein cholesterol levels <70 or >/=190

220 ter publication) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 m

221 PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean differe

222 , including reductions in blood pressure and low-density lipoprotein cholesterol levels and improveme

223 ficantly higher plasma total cholesterol and low-density lipoprotein cholesterol levels compared with

224 Low-density lipoprotein cholesterol levels declined sign

225 n questions about how aggressively to reduce low-density lipoprotein cholesterol levels in ACS.

226 atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 7

227 counted net price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 8

228 rotein receptor protein and increased plasma low-density lipoprotein cholesterol levels on both chow

229 Individuals with elevated fasting low-density lipoprotein cholesterol levels were also ran

230 At the time of study closeout, the low-density lipoprotein cholesterol levels were lower in

231 Higher low-density lipoprotein cholesterol levels were not asso

232 sment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvast

233 and -0.6 to 0.1 mmol/L [-22 to 2 mg/dL] for low-density lipoprotein cholesterol levels).

234 levels and increases in serum creatinine and low-density lipoprotein cholesterol levels.

235 iagnoses, lipid-lowering medication use, and low-density lipoprotein cholesterol levels.

236 For low-density lipoprotein-cholesterol levels, correspondin

237 Low low-density lipoprotein cholesterol, low triglycerides,

238 high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides

239 Extended follow-up of statin-based low-density lipoprotein cholesterol lowering trials impr

240 24% (95% CI, 8-37; P=0.004) despite similar low-density lipoprotein cholesterol lowering.

241 w points to the highlights of the history of low-density lipoprotein-cholesterol lowering, with the d

242 Exposures: Low-density lipoprotein cholesterol-lowering alleles in

243 Results: Low-density lipoprotein cholesterol-lowering genetic var

244 acebo, in addition to effective statin-based low-density lipoprotein cholesterol-lowering treatment.

245 or >/=50 mg/dL (women) and triglycerides and low-density lipoprotein cholesterol <100 mg/dL (n = 780)

246 ntion parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin

247 ncomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl.

248 confidence interval (CI): 0.2, 4.6), higher low-density lipoprotein cholesterol (MD = 1.3 mg/dL, 95%

249 Current smoking, low-density lipoprotein cholesterol, multivessel CAD, di

250 0.0002) and, although not significant, lower low-density lipoprotein cholesterol (n=6502; beta= -4.85

251 Low-density lipoprotein cholesterol, non-high-density li

252 ation score in the 83rd percentile despite a low-density lipoprotein cholesterol of 32 mg/dL.

253 on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive im

254 edicted birth weight was not associated with low density lipoprotein cholesterol or triglycerides, bu

255 nome-wide homozygosity on blood pressure and low density lipoprotein cholesterol, or ten other cardio

256 one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a cr

257 ), duration of stavudine exposure (P < .01), low-density lipoprotein cholesterol (P = .04), and smoki

258 in PCSK9 were associated with 36 mg/dL lower low-density lipoprotein cholesterol (P=3x10(-21)).

259 In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of sm

260 l/L, LF = -0.31 +/- 0.10 mmol/L; P = 0.024), low-density lipoprotein cholesterol (PY = -0.35 +/- 0.10

261 ost in the Exercise group only, secondary to low-density lipoprotein cholesterol reduction (-16%; p =

262 of early initiation of statin treatment for low-density lipoprotein cholesterol reduction in childre

263 Dosing was designed to produce comparable low-density lipoprotein cholesterol reductions, while en

264 is-methylation quantitative trait loci for a low-density lipoprotein cholesterol-related differential

265 (for platelet volume) up to around 20% (for low-density lipoprotein cholesterol), repressed chromati

266 r-also influence levels of triglycerides and low-density lipoprotein cholesterol, respectively.

267 lines from the tails of the white and black low-density lipoprotein cholesterol response distributio

268 NA that regulates LDLR and may contribute to low-density lipoprotein cholesterol response to statin t

269 rimarily focuses on the question of how much low-density lipoprotein cholesterol should be lowered an

270 isk for targets for systolic blood pressure, low-density lipoprotein cholesterol, smoking, physical a

271 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

272 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

273 sed on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCS

274 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lowe

275 Intensive low-density lipoprotein cholesterol therapy with ezetimi

276 Statins for primary prevention based on low-density lipoprotein cholesterol threshold of 4.91 mm

277 ing family history, more stringent age-based low-density lipoprotein cholesterol thresholds, or alter

278 levels of nonfasting remnant cholesterol and low-density lipoprotein cholesterol, through elevated bl

279 trations (high-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol,

280 cant associations for genetic risk scores of low-density lipoprotein-cholesterol, total cholesterol,

281 herosclerotic Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds

282 Also, total cholesterol, low-density lipoprotein cholesterol, triacylglycerol, gl

283 ater weight loss and greater improvements in low-density lipoprotein cholesterol, triglyceride, and g

284 Application of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and b

285 1 microbe intervention in rats reduced serum low-density lipoprotein cholesterol, triglycerides and t

286 Reductions in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and

287 levels high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and

288 high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, triglycerides, bloo

289 ex, fasting plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high

290 ifferences were shown for total cholesterol, low-density lipoprotein cholesterol, triglycerides, or g

291 res reviewed reduced total cholesterol, very low-density lipoprotein cholesterol (VLDL-C) and LDL-C.

292 was 32 mg/dL for men and 38 mg/dL for women, low-density lipoprotein cholesterol was 103 mg/dL, and t

293 The prevalence of high low-density lipoprotein cholesterol was increased among

294 The median admission low-density lipoprotein cholesterol was lower among pati

295 High levels of low-density lipoprotein cholesterol were associated with

296 Reductions in mean levels of total and low-density lipoprotein cholesterol were greater after d

297 s coronary intervention, and higher level of low-density lipoprotein cholesterol were independent pre

298 ensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and

299 IHD from genetically determined obesity were low-density lipoprotein cholesterol with 8%, systolic bl

300 Moreover, lowering of low-density lipoprotein cholesterol with evolocumab redu

301 red in total cholesterol, triglycerides, and low-density lipoprotein cholesterol with the boosted pro